Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
NCT04172844 · Medical College of Wisconsin · PHASE1 · terminated · last registry update 2024-06-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Takeda P3001 study didn't meet primary endpoint of improvement in event-free survival. There is no regulatory path forward for pevonedistat.” | – | Registry record, Medical College of Wisconsin |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-24Phase 3 first posted: BeOne Medicines, Sonrotoclax + Obinutuzumab (NCT06943872)
- 2025-03-13Results posted on the registry: National Cancer Institute (NCI), Azacitidine + Pembrolizumab (NCT04284787)
- 2025-02-28Phase 3 first posted: Janssen Research & Development, LLC, Bleximenib + Venetoclax (VEN) (NCT06852222)
- 2025-02-26Phase 3 first posted: BeOne Medicines, Tacabrutideg + Bendamustine (NCT06846671)
- 2025-01-27Results posted on the registry: National Cancer Institute (NCI), Navitoclax + Trametinib (NCT02079740)
- 2025-01-14Results posted on the registry: AbbVie, Ibrutinib + Venetoclax (NCT04477486)
- 2025-01-08Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Blinatumomab (Group A) + Venetoclax (nonRand Group) (NCT06764238)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-10-22Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Revumenib + Placebo (NCT06652438)
- 2024-10-15Phase 3 first posted: Ascentage Pharma Group Inc., Lisaftoclax (APG-2575) + Azacitidine Injection (NCT06641414)
- 2024-05-24Phase 3 first posted: AbbVie, Venetoclax + Acalabrutinib (NCT06428019)
- 2024-04-23Results posted on the registry: Dana-Farber Cancer Institute, IBRUTINIB + Venetoclax (NCT04273139)
- 2024-03-20Phase 3 first posted: Ascentage Pharma Group Inc., Lisaftoclax (APG-2575) + Acalabrutinib (NCT06319456)
- 2023-10-27Phase 3 first posted: Ascentage Pharma Group Inc., lisaftoclax +BTK inhibitor + BTK inhibitor (NCT06104566)
- 2023-10-10Phase 3 first posted: BeOne Medicines, Sonrotoclax + Zanubrutinib (NCT06073821)
- 2023-10-10Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against BCL2 (NCT06073730)
- 2023-09-18Results posted on the registry: Takeda, Pevonedistat + Venetoclax (NCT04266795)
- 2023-07-17Phase 3 first posted: Merck Sharp & Dohme LLC, Nemtabrutinib + Venetoclax (NCT05947851)
- 2023-07-11Phase 3 first posted: The First Affiliated Hospital of Soochow University, Venetoclax Oral Tablet + Daunorubicin (NCT05939180)
- 2023-06-22Results posted on the registry: City of Hope Medical Center, Romidepsin + Venetoclax (NCT03534180)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision